Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. reports clinical-stage pharmaceutical and intellectual-property developments tied to cannabinoid-based technologies and its majority-owned subsidiary, NeuroThera Labs Inc. The company’s recurring updates cover SCI-110 for Tourette syndrome and Alzheimer’s disease agitation, SCI-210 for autism spectrum disorder and status epilepticus, and combination approaches involving THC, non-psychoactive CBD, PEA and MEAI.
Company news also includes patent activity for CNS, metabolic and antimicrobial-resistance applications; the acquired MUSE™ endoscopic system and related medical-camera intellectual property for GERD procedures; hemp seed oil-based product sales through a controlled subsidiary; and public-company matters such as capital-structure actions, Nasdaq compliance notices, material agreements and financial disclosures.
SciSparc Ltd. (SPRC) has announced the publication of a Japanese divisional patent application for a novel pharmaceutical combination. The patent covers an innovative combination of paracetamol and palmitoylethanolamide (PEA) designed to enhance pain and fever relief while requiring lower doses than traditional paracetamol treatments.
The combination aims to provide a safer and more effective treatment option by leveraging PEA's ability to boost the body's endocannabinoid system. This synergistic approach could potentially reduce the risk of liver damage associated with paracetamol while improving therapeutic outcomes for acute, chronic, and neuropathic pain, as well as fever management.
SciSparc Ltd. (SPRC) and Clearmind Medicine Inc. (CMND) announced the publication of a European patent application for their combination therapy targeting cocaine addiction. The treatment combines Clearmind's MEAI (5-methoxy-2-aminoindane) with SciSparc's Palmitoylethanolamide.
The patent is based on preclinical trials conducted at Bar-Ilan University's Gonda Multidisciplinary Brain Research Center. The research demonstrated that MEAI significantly reduced cocaine-seeking behavior in animals without affecting their natural reward responses, suggesting its specificity in targeting drug-related compulsions. This European patent application adds to existing applications filed in the U.S. and other global territories.
SciSparc (Nasdaq: SPRC) and Clearmind Medicine have filed an international patent application for a novel treatment targeting eating disorders, including anorexia and bulimia. The treatment combines 3-Methylmethcathinone (3-MMC) with SciSparc's Palmitoylethanolamide (PEA).
The collaboration aims to address the complex neurobiological and psychological aspects of eating disorders, which are among the top ten leading causes of disability in young women. Recent statistics show that eating disorders affect up to 70 million people globally, with prevalence rates increasing from 3.4% to 7.8% between 2000 and 2018, particularly among children and adolescents.
SciSparc (Nasdaq: SPRC) and Clearmind Medicine have achieved a significant milestone with the publication of their patent application in South Korea for a novel cocaine addiction treatment. The therapy combines Clearmind's MEAI (5-methoxy-2-aminoindane) with SciSparc's PEA (Palmitoylethanolamide).
The patent application is supported by promising preclinical trial results from Bar-Ilan University's Gonda Multidisciplinary Brain Research Center. The research demonstrated that MEAI significantly reduced cocaine-induced craving in animal subjects without affecting their natural reward responses, such as sucrose seeking behavior. This suggests the treatment specifically targets drug-related compulsions while preserving normal reward mechanisms.
This South Korean patent application adds to the companies' existing intellectual property portfolio, which includes multiple applications filed in the United States and other global territories.
SciSparc (Nasdaq: SPRC) has signed a definitive agreement to sell its entire 52.73% ownership stake in MitoCareX Bio , a cancer therapeutics drug discovery company, to N2OFF Inc. (Nasdaq: NITO). The transaction includes:
- $700,000 cash payment for 4,961 MitoCareX shares
- Exchange of remaining shares for 40% of N2OFF's fully diluted capital stock
- Potential additional N2OFF stock up to 25% based on milestones
- 30% share of N2OFF's financing proceeds over 5 years (max $1.6M)
- N2OFF's commitment to invest $1M in MitoCareX post-closing
The deal requires N2OFF shareholder approval and must close within 30 days. Dr. Alon Silberman will continue as CEO with a 5% restricted stock grant vesting over 3 years. Upon completion, MitoCareX will become a wholly-owned subsidiary of N2OFF.
SciSparc (Nasdaq: SPRC) has provided a new $2 million loan to AutoMax Motors to support its business expansion in direct importing of JAC electric vehicles. The loan carries an 8% annual interest rate, repayable in monthly installments of $50,000 plus interest, with an early repayment option without penalties.
This new funding follows previous bridge loans totaling $4.25 million provided as part of a merger agreement signed in April 2024. The interest will be cancelled upon merger completion, with AutoMax continuing principal payments. The loan is secured by a first-ranking fixed charge on AutoMax's subsidiary shares.
The merger agreement, signed in April 2024, will see SciSparc acquire 100% of AutoMax, marking its expansion into the automotive sector. The deal remains subject to customary closing conditions and shareholder approvals from both companies.
SciSparc (Nasdaq: SPRC) has reached a significant settlement agreement regarding a lawsuit it filed in February 2022 against six former directors. The settlement, approved through court-mediated negotiations, includes a $411,000 cash payment to SciSparc from the defendants.
The lawsuit alleged breaches of fiduciary duties under Israeli Companies Law related to a prior pain clinic network acquisition. A key component of the settlement is the termination of a disputed licensing agreement with Dekel Pharmaceuticals , effective February 5, 2024. This agreement had been established with the company's former chairman and CEO, Dr. Ascher Shmulewitz, in May 2015.
The settlement ensures SciSparc retains exclusive global rights to its IP portfolio, patents, know-how, and technologies, while being released from all commitments, claims, and royalties related to the License Agreement. Dekel will take ownership of patent applications for inflammatory disorder treatments, which are unrelated to SciSparc's current pipeline.
SciSparc (Nasdaq: SPRC) has announced a significant development in its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND), as Clearmind secured a patent publication in Mexico for a novel combination treatment. The patent covers the innovative combination of MDMA with N-Acylethanolamines, targeting various binge behaviors including alcohol, eating, tobacco, shopping, and sexual conduct.
The treatment combines SciSparc's N-Acylethanolamines therapy with Clearmind's MEAI (5-methoxy-2-aminoindane). This collaborative research effort has resulted in 13 patent applications filed with the U.S. Patent and Trademark Office and other global jurisdictions, demonstrating the companies' commitment to developing new therapies for disorders and rare diseases of the central nervous system.
SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company focused on central nervous system disorders, has received a 180-day extension from Nasdaq until July 14, 2025 to regain compliance with the minimum bid price requirement. The company must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days to meet compliance.
This extension follows an initial notification from Nasdaq on July 16, 2024, which gave SciSparc 180 days until January 13, 2025, to meet the requirement. The company was granted the additional period after meeting all other Nasdaq Capital Market initial listing requirements except the bid price rule. SciSparc has indicated its intention to cure the deficiency, including the possibility of implementing a reverse share split if necessary.
The notification has no immediate impact on SciSparc's listing status, and its shares continue trading on the Nasdaq Capital Market under the symbol 'SPRC'.
SciSparc (Nasdaq: SPRC) announced that AutoMax Motors, with which it has a pending merger agreement, received its first $13 million shipment of vehicles from JAC Motors, a Chinese automotive manufacturer. This development follows regulatory approvals for direct importation in Israel and marks AutoMax's entry into direct import and distribution operations.
JAC Motors specializes in electric vehicles (EVs), offering both passenger and commercial vehicles supported by advanced R&D and battery technologies. AutoMax aims to leverage JAC's EV lineup to meet Israel's growing demand for sustainable transportation.
SciSparc has provided financial support to AutoMax to facilitate the JAC Motors transaction. The merger agreement between SciSparc and AutoMax, signed in April 2024, is subject to shareholders' approval from both companies and would enable SciSparc's expansion into the automotive sector.